
    
      This study will evaluate the efficacy, safety, tolerability,pharmacokinetics (PK), and
      pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent
      and chronic ITP patients who have failed to respond or relapsed after prior therapy, with a
      platelet count <30,000/ÂµL. on 2 occasions at least 7 days apart with the confirmatory count
      on the first day of treatment.

      subjects will participate in 3 treatment groups (24 subjects in each of the active treatment
      groups and 12 subjects in the placebo group). The total study duration will be 20 weeks per
      subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period,
      and 4 weeks of follow-up period.
    
  